
Opinion|Videos|April 23, 2024
FDA Approval Pathway for Prescription Digital Therapeutics
Mahsa Salsabili, PharmD, PhD, delves into the FDA approval process for prescription digital therapeutics , which requires market approval, clinical studies and real-world evidence, to establish their efficacy in treating the targeted disease or condition.
Advertisement
Episodes in this series

Advertisement
Related to this article

A Massachusetts federal court threw out HRSA grant terms that kept Ryan White clinics from offering gender-affirming care to patients with HIV.

Only 43% of community oncologists feel very comfortable with new immunotherapies. Prerna Mewawalla, M.D., of Allegheny Health Network talks safety protocols and trial access.

Among 16 Black transgender women, 15 with HIV, risk awareness, comfort, provider trust and support shaped whether they completed HRA, according to a new qualitative study.

A Centene OB-GYN and an AAFP family physician explain how health plans, primary care and policy can help close rural maternity care gaps.

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Federal judge vacates HRSA limits on gender-affirming care in Ryan White HIV program
2
Closing rural maternity care gaps starts close to home, Centene and AAFP leaders say
3
Bringing CAR T and bispecifics closer to home with Prerna Mewawalla, M.D.
4
Quick Q&A: Jeff Dunn, Pharm.D., MBA, on 340B discounts and PBM rebates
5


